Godavari Drugs

Who are the top shareholders of the Godavari Drugs?

The top shareholders of Godavari Drugs include promoter Sushma Kakani with 15.34%, Highcrestt Global Company Ltd as the largest public shareholder at 2.66%, and individual investors holding a combined 39.93%. There are currently no mutual funds or foreign institutional investors in the company.

The top shareholders of Godavari Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sushma Kakani, with a stake of 15.34%. Additionally, Highcrestt Global Company Ltd is the highest public shareholder, owning 2.66% of the company. Individual investors collectively hold 39.93% of the shares. Notably, there are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

how big is Godavari Drugs?

As of Jun 06, Godavari Drugs Ltd has a market capitalization of 72.67 Cr, classifying it as a Micro Cap company, with recent net sales of 113.35 Cr and a net profit of 4.38 Cr over the last four quarters.

Market Cap: As of Jun 06, Godavari Drugs Ltd has a market capitalization of 72.67 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest 4 quarters, Godavari Drugs reported a sum of Net Sales of 113.35 Cr and a sum of Net Profit of 4.38 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is also Standalone data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 38.97 Cr, and the Total Assets amount to 134.75 Cr.

Who are in the management team of Godavari Drugs?

As of March 2023, the management team of Godavari Drugs includes Mukund Kakani (Managing Director), Mohit Jaju (Whole Time Director & CFO), and several non-executive directors, including Ghanshyam Jaju (Chairman) and S A Hussain. Venkatesh Achanta serves as the Company Secretary & Compliance Officer.

As of March 2023, the management team of Godavari Drugs includes the following individuals:<BR><BR>1. Mukund Kakani - Managing Director<BR>2. S A Hussain - Non-Executive & Independent Director<BR>3. Mohit Jaju - Whole Time Director & CFO<BR>4. Ramesh Babu Telugu - Non-Executive & Independent Director<BR>5. Vimala B Madon - Non-Executive & Independent Director<BR>6. Ghanshyam Jaju - Chairman (Non-Executive)<BR>7. Mahindra Uday Bhalerao - Non-Executive Director<BR>8. Venkatesh Achanta - Company Secretary & Compliance Officer<BR><BR>As of March 2023, the management team of Godavari Drugs comprises a diverse group of directors and executives, each holding specific roles within the company.

When is the next results date for Godavari Drugs?

No Upcoming Board Meetings

Has Godavari Drugs declared dividend?

No Dividend History Available

Who are the peers of the Godavari Drugs?

Godavari Drugs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vivo Bio Tech. In terms of management risk, growth, and capital structure, Sun Pharma and Cipla perform excellently, while Godavari Drugs shows average management risk and below-average growth.

Peers: The peers of Godavari Drugs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vivo Bio Tech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness, Godavari Drugs, Vivo Bio Tech, and Vasundhara Rasy. Below Average management risk is noted for Lasa Supergeneri and Sunil Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Rajnish Wellness, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Godavari Drugs, Vivo Bio Tech, Lasa Supergeneri, and Sunil Healthcare. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma, Average for Lasa Supergeneri, and Below Average for Rajnish Wellness, Godavari Drugs, Sunil Healthcare, and Vivo Bio Tech.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Rajnish Wellness has the lowest at -83.99%. Godavari Drugs has a 1-year return of 3.44%, which is significantly higher than Rajnish Wellness but lower than Divi's Lab. Additionally, the peers with negative six-month returns include Rajnish Wellness, Lasa Supergeneri, Sunil Healthcare, and Vasundhara Rasy.

What is the technical trend for Godavari Drugs?

As of May 30, 2025, Godavari Drugs shows a mildly bearish trend, influenced by daily moving averages and monthly indicators, despite mixed signals from weekly MACD and KST.

As of 30 May 2025, the technical trend for Godavari Drugs has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, creating a mixed signal. The monthly MACD and Bollinger Bands are bearish, which adds to the overall bearish sentiment. The RSI shows no signal in both weekly and monthly time frames, indicating a lack of momentum. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly indicators.

What does Godavari Drugs do?

Godavari Drugs Limited manufactures Active Pharmaceutical Ingredients (API) and drug intermediates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 255 Cr and a net profit of 9 Cr, with a market cap of INR 66 Cr.

Overview: <BR>Godavari Drugs Limited is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in an unspecified year and has maintained its status as a manufacturer of pharmaceutical products. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 255 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 66 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 15.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.34 <BR>Return on Equity: 10.51% <BR>Price to Book: 1.61 <BR><BR>Contact Details: <BR>Address: Mayfair 1-8-303-34, Sardar Patel Road Secunderabad Andhra Pradesh : 500003 <BR>Tel: 91-40-27849700/27844557 <BR>Email: info@godavaridrugs.com <BR>Website: http://www.godavaridrugs.com

Is Godavari Drugs overvalued or undervalued?

As of September 18, 2025, Godavari Drugs is considered very attractive and undervalued, with a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%, significantly lower than peers like Sun Pharma and Divi's Lab, while also showing strong long-term growth potential despite recent underperformance against the Sensex.

As of 18 September 2025, the valuation grade for Godavari Drugs has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%. <BR><BR>In comparison to its peers, Godavari Drugs stands out with a much lower PE ratio than Sun Pharma (34.46) and Divi's Lab (70.44), both of which are classified as expensive. Additionally, Godavari's PEG ratio is notably at 0.00, suggesting strong growth potential relative to its price. While the stock has underperformed the Sensex over the past year, its recent 5-year return of 136.84% compared to the Sensex's 113.70% highlights its long-term value proposition.

How has been the historical performance of Godavari Drugs?

Godavari Drugs has shown a declining trend in net sales and profits over the past two years, with net sales dropping from 159.62 Cr in Mar'23 to 113.35 Cr in Mar'25, while total assets and liabilities have increased, indicating rising debt levels. Operating profit margins improved slightly, but overall financial performance reflects challenges in the market.

Answer:<BR>The historical performance of Godavari Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Godavari Drugs reported net sales of 113.35 Cr in Mar'25, a decline from 156.71 Cr in Mar'24 and 159.62 Cr in Mar'23, indicating a downward trend in revenue. The total operating income followed a similar pattern, decreasing from 156.71 Cr in Mar'24 to 113.35 Cr in Mar'25. Raw material costs also decreased to 85.24 Cr in Mar'25 from 121.95 Cr in Mar'24, while total expenditure fell to 101.52 Cr in Mar'25 from 143.41 Cr in Mar'24. Operating profit, excluding other income, was 11.83 Cr in Mar'25, slightly lower than 13.30 Cr in Mar'24, but the operating profit margin improved to 10.44%. Profit before tax decreased to 5.63 Cr in Mar'25 from 6.92 Cr in Mar'24, and profit after tax also fell to 4.38 Cr from 5.55 Cr. The company's total assets increased to 143.08 Cr in Mar'25 from 134.75 Cr in Mar'24, while total liabilities rose to 143.08 Cr from 134.75 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 11.00 Cr in Mar'25 from 18.00 Cr in Mar'24, while cash flow from investing activities worsened to -19.00 Cr. Overall, Godavari Drugs has experienced a decline in sales and profits, alongside an increase in total assets and liabilities, reflecting a challenging financial environment.

Are Godavari Drugs Ltd latest results good or bad?

Godavari Drugs Ltd's latest results show mixed performance, with a slight increase in net sales but a decline in net profit and operating margin, indicating financial challenges. Overall, the results are more concerning than positive, reflecting issues with profitability and high leverage.

The latest results for Godavari Drugs Ltd indicate a mixed performance, with several concerning trends. In Q2 FY26, the company reported net sales of ₹26.65 crores, which reflects an 11.93% increase from the previous quarter but only a modest 2.15% growth year-on-year. However, the net profit decreased to ₹1.00 crore, down 8.26% compared to the same quarter last year, highlighting a decline in profitability.<BR><BR>The operating margin has also seen a significant drop, falling to 7.47% from 11.12% in the same quarter last year, indicating pressure from rising input costs and competitive pricing. Additionally, the return on equity (ROE) has declined to 8.54%, which is below the acceptable threshold for quality pharmaceutical businesses.<BR><BR>The company is facing challenges such as high leverage, with a net debt-to-equity ratio of 1.37, which raises concerns about financial flexibility. Furthermore, the stock has underperformed significantly over the past year, declining 12.99% compared to the broader market's gains.<BR><BR>Overall, while there are some signs of sequential improvement in revenue, the overall financial health and profitability metrics suggest that the results are more concerning than positive, indicating a challenging environment for the company moving forward.

Should I buy, sell or hold Godavari Drugs Ltd?

Why is Godavari Drugs Ltd falling/rising?

As of 17-Mar, Godavari Drugs Ltd's stock price is rising to 82.90, driven by a trend reversal, increased investor participation, and outperformance against its sector. Despite short-term strength, it remains below its 50-day and 200-day moving averages, indicating potential long-term pressure.

As of 17-Mar, Godavari Drugs Ltd's stock price is rising, currently at 82.90, with a change of 0.92 (1.12%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a trend reversal, gaining after two consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has outperformed its sector by 0.84%, suggesting that it is gaining traction compared to its peers.<BR><BR>Investor participation has also increased significantly, with a delivery volume of 19.01k on 16 March, which is a remarkable rise of 639.04% against the 5-day average delivery volume. This surge in trading activity often reflects growing investor interest and confidence in the stock, contributing to its price increase.<BR><BR>Moreover, the stock's current price is higher than its 5-day, 20-day, and 100-day moving averages, which typically indicates a bullish trend. However, it remains lower than its 50-day and 200-day moving averages, suggesting that while there is short-term strength, it may still be under pressure in the longer term.<BR><BR>Overall, the combination of a trend reversal, increased investor participation, and outperformance against the sector are key reasons for the rising stock price of Godavari Drugs Ltd.

Why is Godavari Drugs Ltd falling/rising?

As of 18-Mar, Godavari Drugs Ltd's stock price is rising to 87.99, reflecting a 6.99% increase. This upward trend is supported by strong performance against its sector, consistent gains over the past two days, and trading above key moving averages, despite a drop in investor participation.

As of 18-Mar, Godavari Drugs Ltd's stock price is rising, currently at 87.99, reflecting a change of 5.75 or 6.99% increase. This upward movement can be attributed to several factors. The stock has outperformed its sector by 6.72% today and has shown a consecutive gain over the last two days, with a total return of 7.33% during this period. Additionally, the stock opened with a gain of 2.12% today and reached an intraday high of Rs 87.99.<BR><BR>The stock is also trading above its moving averages for 5 days, 20 days, 50 days, 100 days, and 200 days, indicating a strong bullish trend. Furthermore, despite a decrease in investor participation, with delivery volume falling by 52.75% against the 5-day average, the stock remains liquid enough for trading. Overall, these factors contribute to the positive momentum in Godavari Drugs Ltd's stock price.

Why is Godavari Drugs Ltd falling/rising?

As of 19-Mar, Godavari Drugs Ltd's stock price is at 85.05, down 1.87% after a trend reversal. Despite a weekly gain of 1.29%, the stock has underperformed over the past year with an 11.87% decline, amid decreased investor participation and a negative sentiment in the sector.

As of 19-Mar, Godavari Drugs Ltd's stock price is falling, currently at 85.05, reflecting a change of -1.62 (-1.87%). This decline follows a trend reversal after two consecutive days of gains. The stock opened significantly lower today, with a loss of -3.08%, and reached an intraday low of Rs 83.27, which is a decrease of -3.92%. <BR><BR>Despite outperforming its sector by 0.28% today, the overall performance in the short term shows a mixed picture. Over the past week, the stock has gained +1.29%, while the benchmark Sensex has dropped by -2.40%. However, in the longer term, the stock has underperformed with a -11.87% decline over the past year compared to a -1.65% drop in the Sensex. <BR><BR>Additionally, there has been a notable decrease in investor participation, with delivery volume falling by -31.18% against the 5-day average. The stock's liquidity remains adequate, but the overall sentiment in the Pharmaceuticals & Drugs sector has also declined by -2.13%. This combination of factors contributes to the current downward movement in Godavari Drugs Ltd's stock price.

Why is Godavari Drugs Ltd falling/rising?

As of 20-Mar, Godavari Drugs Ltd's stock price is currently Rs 82.50, reflecting a 2.99% decrease and part of a broader trend of underperformance, with a 13.28% decline over the past year. Despite a positive year-to-date performance of 7.38%, recent trading shows increased selling pressure and a lack of price stability.

As of 20-Mar, Godavari Drugs Ltd's stock price is falling, currently at Rs 82.50, which reflects a decrease of Rs 2.54 or 2.99%. This decline is part of a broader trend, as the stock has been underperforming, having lost 4.81% over the last two days. Additionally, the stock has underperformed its sector by 4.69% today.<BR><BR>In terms of recent performance, the stock has shown a negative return of 1.53% over the past month, while the year-to-date performance is positive at 7.38%. However, the stock has experienced a significant decline of 13.28% over the past year, contrasting with a modest decline of 2.38% in the benchmark index, Sensex.<BR><BR>Today's trading activity indicates a low point, with the stock touching an intraday low of Rs 82.2, down 3.34%. The weighted average price suggests that more volume was traded closer to this low price, indicating selling pressure. Although there has been a rise in investor participation, with delivery volume increasing by 34.77% compared to the five-day average, this has not translated into price stability or growth.<BR><BR>Overall, the combination of recent consecutive falls, underperformance against the sector, and the stock's current trading dynamics contribute to the observed decline in Godavari Drugs Ltd's stock price.

Why is Godavari Drugs Ltd falling/rising?

As of 23-Mar, Godavari Drugs Ltd's stock price is rising to 84.00, reflecting a 1.27% increase. This rise is due to strong buying interest and a trend reversal despite the company's weak long-term fundamentals and recent profit declines.

As of 23-Mar, Godavari Drugs Ltd's stock price is rising, currently at 84.00, reflecting a change of 1.05 (1.27%) upward. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 4.84% today, indicating a positive performance relative to the broader market. Additionally, the stock opened with a gain of 2.23% and reached an intraday high of Rs 86.79, which is a 4.63% increase, suggesting strong buying interest at the start of the trading session.<BR><BR>Moreover, the stock has experienced a trend reversal after two consecutive days of decline, signaling a potential shift in investor sentiment. Despite the overall negative performance of the Pharmaceuticals & Drugs sector, which has fallen by 3.58%, Godavari Drugs Ltd's ability to gain today indicates resilience in its stock performance.<BR><BR>However, it is important to note that while the stock is currently rising, it has faced challenges in the past year, generating a return of -11.86% and experiencing a significant drop in profits by 43.4%. The company's long-term fundamentals are weak, with a -2.98% CAGR growth in net sales over the last five years and a high Debt to EBITDA ratio of 3.27 times, which raises concerns about its financial health. Despite these issues, the current upward movement in stock price reflects short-term positive trading dynamics.

Why is Godavari Drugs Ltd falling/rising?

As of 24-Mar, Godavari Drugs Ltd's stock price is rising to Rs 88.95, reflecting a 3.43% increase. The stock has outperformed the Sensex significantly over various time frames, despite a recent decline in investor participation.

As of 24-Mar, Godavari Drugs Ltd's stock price is rising, currently at Rs 88.95, reflecting a change of Rs 2.95 or 3.43% increase. This upward movement is supported by several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 8.16% compared to the Sensex's decline of 2.63%. Additionally, in the last month, the stock has risen by 9.94%, while the Sensex has fallen by 9.92%. Year-to-date, Godavari Drugs has shown a strong performance with a 15.78% increase, contrasting with the Sensex's drop of 13.09%.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 2.31% and has experienced consecutive gains over the last two days, accumulating a total return of 7.23% during this period. The stock reached an intraday high of Rs 89.5, marking a 4.07% increase, although it also saw a low of Rs 84, which was a decrease of 2.33%. Importantly, Godavari Drugs is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a positive trend.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume on 23 March falling by 12.4% compared to the 5-day average. Despite this decrease in participation, the overall liquidity remains sufficient for trading. Overall, the combination of strong recent performance, positive returns compared to benchmarks, and trading above moving averages contributes to the rising stock price of Godavari Drugs Ltd.

Why is Godavari Drugs Ltd falling/rising?

As of 25-Mar, Godavari Drugs Ltd's stock price is rising to Rs 90.00, reflecting a 2.99% increase. The stock has outperformed the Sensex and shows strong performance metrics, positive investor sentiment, and favorable technical indicators.

As of 25-Mar, Godavari Drugs Ltd's stock price is rising, currently at Rs 90.00, which reflects a change of Rs 2.61 or 2.99% increase. This upward movement can be attributed to several factors. Over the past week, the stock has gained 3.84%, significantly outperforming the Sensex, which declined by 1.87%. In the last month, the stock has risen by 13.79%, while the Sensex fell by 8.51%. Year-to-date, Godavari Drugs has shown a positive return of 17.14%, contrasting with the Sensex's decline of 11.67%.<BR><BR>Today, the stock has outperformed its sector by 1.1% and has been on a consecutive gain streak for the last three days, accumulating a total return of 8.5% during this period. The stock reached an intraday high of Rs 90.9, marking a 4.02% increase, although it also experienced a low of Rs 82, indicating a wide trading range of Rs 8.9 and high volatility of 5.15% today.<BR><BR>Additionally, Godavari Drugs is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator. There has also been a notable increase in investor participation, with delivery volume rising by 74.89% compared to the 5-day average. This combination of strong performance metrics, positive investor sentiment, and technical indicators contributes to the stock's rising price.

Which are the latest news on Godavari Drugs?